Original Research Article I Volume 5 I Issue 4 I 2017

Screening for Chronic Hepatitis B Virus Infection in Patients with Malignancies and Assessment of the Impact of Malignancies on the Response to Preemptive Treatment of Chronic Hepatitis B Virus

Abd Elfatah Fahmy Hanno, Mohamed Sobhy Elshazly, Abbas Mohamed Omar, Hossam Eldin Fathy Ahmed, Mohamed Mahmoud Mohamed Ismaail

Biolife; 2017, 5(4), pp 578-584

DOI:https://doi.org/10.5281/zenodo.7393362

Abstract:

The prevalence of hepatitis B virus (HBV) infection in patients with malignancies especially haematological malignancies is increased compared with the general population worldwide. HBV reactivation is common following chemotherapy and is associated with a high mortality despite prompt anti-viral treatment. HBV reactivation may necessitate interruption of chemotherapy with adverse prognostic consequences for the haematological disease.

Keywords:

Hepatitis B virus, Preemptive treatment, Entecavir, Malignancies.

References:

  1. Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012; 56:422-33.
  2. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39:222–30.
  3. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40.
  4. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, De LV, et al. Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242–7.
  5. Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012;32:612–21.
  6. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47:380 384.
  7. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-p ositive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889–96.
  8. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206–17.
  9. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–20.
  10. Menéndez-Arias L, Álvarez M, Pacheco B. 217. Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861–7.
  11. Maepa MB, Roelofse I, Ely A, Arbuthnot P. Progress and prospects of ant-HBV gene therapy development. Int J Mol Sci 2015; 16: 17589–610.
  12. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zincfinger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947–54...

Article Dates:

Received: 05 October 2017; Accepted: 26 November 2017; Published: 05 December 2017

How To Cite:

Abd Elfatah Fahmy Hanno, Mohamed Sobhy Elshazly, Abbas Mohamed Omar, Hossam Eldin Fathy Ahmed, & Mohamed Mahmoud Mohamed Ismaail. (2022). Screening for Chronic Hepatitis B Virus Infection in Patients With Malignancies and Assessment of the Impact of Malignancies on the Response To Preemptive Treatment of Chronic Hepatitis B Virus. Biolife, 5(4), 578–584. https://doi.org/10.5281/zenodo.7393362

Download Full Paper: PDF

Logo


Logo